Detail of the clinical trial

Title of the trial An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with 400 mg Imatinib
EudraCT number 2011-006181-41
Protocol number CA180399
Sponsor Bristol-Myers Squibb International Corporation,Chaussée de La Hulpe 185,Brussels,1170
Indications Oncology
Diagnosis Chronic Myeloid Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2012
Date of approval by Institute (SÚKL) 17.1.2013
Date of approval by EC 11.1.2013
Date of initiation CT in ČR 7.11.2013
Date of ending CT in ČR
Sites Fakultni nemocnice Olomouc,Hematoonkologicka klinika, I.P.Pavlova 6,Olomouc, 775 20 (discontinued)
Fakultni nemocnice Kralovske Vinohrady,Interní hematologická klinika,Srobarova 50,Praha 10,100 34 (discontinued)
Fakutni nemocnice Brno,Interní hematologická a onkologická klinika,Jihlavska 20,Brno,625 00 (discontinued)
Fakultni nemocnice Hradec Kralove,2.interni klinika,odd. klinicke hemalologie ,Sokolska 581,Hradec Kralove,500 05 (discontinued)
Ústav hematologie akrevní transfůze, U nemocnice 1,128 00 Praha 2

‹‹ Back to list